30/06/2026 20:17
|
Medical, Health & Aged Care
Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFS
MANGROVE is...